0001140361-14-046335.txt : 20141223 0001140361-14-046335.hdr.sgml : 20141223 20141223171041 ACCESSION NUMBER: 0001140361-14-046335 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141219 FILED AS OF DATE: 20141223 DATE AS OF CHANGE: 20141223 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OncoMed Pharmaceuticals Inc CENTRAL INDEX KEY: 0001302573 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 383572512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 800 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-995-8200 MAIL ADDRESS: STREET 1: 800 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pollard-Knight Denise CENTRAL INDEX KEY: 0001297000 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35993 FILM NUMBER: 141307651 MAIL ADDRESS: STREET 1: C/O IDENIX PHARMACEUTICALS, INC. STREET 2: 60 HAMPSHIRE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc1.xml FORM 4 X0306 4 2014-12-19 0 0001302573 OncoMed Pharmaceuticals Inc OMED 0001297000 Pollard-Knight Denise C/O ONCOMED PHARMACEUTICALS, INC. 800 CHESAPEAKE DRIVE REDWOOD CITY CA 94063 1 0 0 0 Common Stock 2014-12-19 4 S 0 20654 21.7057 D 1964915 I See Footnote This transaction was executed in multiple trades in prices ranging from $21.60 to $21.87, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The shares of common stock of OMED are owned by Phase4 Ventures III LP ("Phase4"). The Reporting Person is a partner of Phase4 Partners Limited, which is the manager of Phase4. The Reporting Person disclaims beneficial ownership of the reported securities held by Phase4 except to the extent of her pecuniary interest therein. /s/ Alicia J. Hager, Attorney-in-Fact for Denise Pollard-Knight 2014-12-23